Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

BEAM

Beam Therapeutics Inc

Sep 20 • 03:01PM ET

25.89

Dollar change -0.15
Percentage change -0.58	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: ARKK VTI IWM VB ARKG XBI VBK VXF IWN IBB

Index	RUT	P/E	-	EPS (ttm)	-1.80	Insider Own	13.13%	Shs Outstand	81.63M	Perf Week	-1.56%
Market Cap	2.13B	Forward P/E	-	EPS next Y	-4.67	Insider Trans	-1.60%	Shs Float	71.60M	Perf Month	1.57%
Income	-143.01M	PEG	-	EPS next Q	-1.19	Inst Own	81.40%	Short Float	15.48%	Perf Quarter	12.86%
Sales	352.57M	P/S	6.05	EPS this Y	-173.40%	Inst Trans	-0.68%	Short Ratio	10.31	Perf Half Y	-25.92%
Book/sh	10.37	P/B	2.50	EPS next Y	0.60%	ROA	-10.94%	Short Interest	11.08M	Perf Year	2.62%
Cash/sh	12.23	P/C	2.12	EPS next 5Y	-3.70%	ROE	-17.17%	52W Range	16.95 - 49.50	Perf YTD	-4.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.58%	ROI	-14.21%	52W High	-47.70%	Beta	1.85
Dividend TTM	-	Quick Ratio	5.81	Sales past 5Y	43297.50%	Gross Margin	93.24%	52W Low	52.74%	ATR (14)	1.37
Dividend Ex-Date	Feb 04, 2014	Current Ratio	5.81	EPS Y/Y TTM	60.97%	Oper. Margin	-52.31%	RSI (14)	53.18	Volatility	5.54% 5.46%
Employees	436	Debt/Eq	0.19	Sales Y/Y TTM	339.83%	Profit Margin	-40.56%	Recom	1.94	Target Price	50.36
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	-2.01%	Payout	-	Rel Volume	0.57	Prev Close	26.04
Sales Surprise	-16.95%	EPS Surprise	1.52%	Sales Q/Q	-41.48%	Earnings	Aug 06 BMO	Avg Volume	1.07M	Price	25.89
SMA20	2.56%	SMA50	-1.59%	SMA200	-5.26%	Trades		Volume	525,674	Change	-0.58%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Initiated	H.C. Wainwright	Buy	$80
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight	$38 → $40
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$35
Dec-08-23	Downgrade	Jefferies	Buy → Hold	$75 → $30
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform	$75 → $20
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Mar-21-23	Initiated	Bernstein	Mkt Perform	$37
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$62
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$61 → $66
Dec-13-22	Initiated	Citigroup	Buy	$62
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$41
Apr-28-22	Initiated	Credit Suisse	Neutral	$62
Jan-05-22	Initiated	Guggenheim	Buy	$130
Oct-19-21	Initiated	SVB Leerink	Outperform	$117
Sep-24-21	Resumed	Stifel	Buy	$85 → $120
Sep-10-21	Initiated	BofA Securities	Buy	$150
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform	$85
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight	$47 → $90
Feb-16-21	Initiated	Wells Fargo	Overweight	$145

Show Previous Ratings

Sep-05-24 11:31AM	Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report? (Zacks)
Aug-14-24 10:27AM	Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine with CRISPR Technology (Insider Monkey)
Aug-09-24 10:19AM	3 Gene Editing Stocks with Potential to Transform Medicine (InvestorPlace)
Aug-07-24 10:50AM	Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss (Zacks)
Aug-06-24 01:54PM	BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace)
07:45AM	Loading…
07:45AM	Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-26-24 07:43AM	Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock? (Zacks)
Jul-24-24 06:28PM	Beam Therapeutics Stock Earns RS Rating Jump To 85 (Investor's Business Daily) +7.92%
08:53AM	CRISPR Therapeutics Nears 52-Week Low. Time to Buy? (TipRanks)
08:23AM	Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40 (InvestorPlace)
Jul-22-24 04:45PM	3 Gene Editing Stocks Shaping the Future of Medicine (InvestorPlace) +12.09%
Jul-17-24 07:45AM	Caribou lays off staff; Roche walks away from Relay (BioPharma Dive)
Jul-16-24 10:12AM	Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines (Zacks) +6.52%
Jul-15-24 06:30AM	Beam Therapeutics Announces Transition of Chief Financial Officer (GlobeNewswire)
12:56PM	Loading…
Jul-11-24 12:56PM	Here's Why You Should Invest in Beam Therapeutics (BEAM) Now (Zacks) +8.01%
Jul-09-24 12:00PM	Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
07:00AM	The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 (InvestorPlace)
06:25AM	3 Stocks With the Potential to 10X Your Money (InvestorPlace)
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
Jul-03-24 09:12AM	3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030 (InvestorPlace)
Jun-27-24 10:02PM	You've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever. (InvestorPlace)
10:26AM	Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study (Zacks)
Jun-26-24 06:30AM	Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Jun-14-24 03:00AM	Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease (GlobeNewswire)
Jun-06-24 11:31AM	Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report? (Zacks)
May-30-24 06:30AM	Beam Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 04:00PM	Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress (GlobeNewswire)
May-13-24 02:18PM	15 Best ARK Stocks To Buy Now (Insider Monkey) +12.98%
May-09-24 06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
10:52AM	Loading…
May-08-24 10:52AM	Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss (Zacks)
06:30AM	Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference (GlobeNewswire)
May-07-24 09:02PM	Beam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed Overview (GuruFocus.com)
01:54PM	BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
10:17AM	Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates (MT Newswires)
06:30AM	Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results (GlobeNewswire)
May-01-24 10:01AM	Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Mar-28-24 11:30AM	Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report? (Zacks)
Mar-26-24 06:30AM	Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Feb-28-24 06:30AM	Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences (GlobeNewswire)
Feb-27-24 04:01PM	Beam Rockets 26%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug (Investor's Business Daily) +25.89%
02:57PM	Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat (Investor's Business Daily)
12:33PM	Beam Shares Rise As Q4 Results Beat Street (RTT News)
07:11AM	Beam Therapeutics Inc (BEAM) Reports Strong Year-End Financials with Key Clinical Milestones on ... (GuruFocus.com)
06:30AM	Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones (GlobeNewswire)
Feb-20-24 10:00AM	Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline (Zacks)
Feb-16-24 02:46PM	Beam Therapeutics Stock Shows Healthy Relative Strength Improvement (Investor's Business Daily)
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-07-24 07:35AM	3 Biotech Stocks to Buy on the Dip: February 2024 (InvestorPlace)
Feb-05-24 06:30AM	Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 06:21PM	Why Beam Therapeutics Stock Zoomed 17% Higher Today (Motley Fool) +16.47% -8.66%
Jan-16-24 01:51PM	Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market (InvestorPlace)
09:00AM	3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street (Motley Fool)
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace)
Jan-08-24 06:30AM	Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones (GlobeNewswire) +6.87%
05:52AM	4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 (Motley Fool)
Jan-02-24 06:30AM	Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-23 10:30AM	2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street (Motley Fool)
Dec-15-23 10:22AM	11 Most Promising Biotech Stocks to Buy According to Analysts (Insider Monkey)
Dec-14-23 06:30AM	Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors (GlobeNewswire) +5.34%
Dec-08-23 11:30AM	Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report? (Zacks) -8.17%
Nov-30-23 09:55AM	Wall Street Analysts Believe Beam Therapeutics Inc. (BEAM) Could Rally 81.29%: Here's is How to Trade (Zacks)
Nov-23-23 11:03AM	Beam Therapeutics Inc's Chief Legal Officer Christine Bellon Sells 10,000 Shares (GuruFocus.com)
09:42AM	14 Best Short-Term Stocks to Invest In (Insider Monkey)
Nov-20-23 05:43PM	The 3 Best Gene Editing Stocks on the Frontier of Medicine (InvestorPlace) +11.98% -9.14%
Nov-18-23 07:15AM	Is Beam Therapeutics Stock a Buy Now? (Motley Fool)
06:49AM	3 Monster Stocks in the Making (Motley Fool)
Nov-17-23 12:00PM	What Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock (Zacks) +10.81%
Nov-14-23 05:50AM	Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks (Motley Fool) +11.90%
Nov-10-23 09:55AM	Does Beam Therapeutics Inc. (BEAM) Have the Potential to Rally 139.76% as Wall Street Analysts Expect? (Zacks)
Nov-09-23 01:04PM	Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates (Zacks)
Nov-08-23 06:30AM	Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference (GlobeNewswire) -8.36%
06:30AM	Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:02AM	Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners (Investor's Business Daily)
Nov-05-23 08:30AM	2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now (Motley Fool)
Nov-01-23 05:40AM	Inside Cathie Woods Portfolio: 3 Stocks She Is Betting Millions On (InvestorPlace)
Oct-31-23 07:09PM	Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today (Motley Fool) +10.62%
04:04PM	Verve Stock Soars On $250 Million Eli Lilly Deal (Investor's Business Daily)
10:01AM	Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should Know (Zacks)
10:00AM	After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy? (Motley Fool)
06:00AM	Beam Announces Agreement for Lilly to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease (GlobeNewswire)
05:00AM	Lilly buys out Beam in heart drug alliance with Verve (BioPharma Dive)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
10:00AM	Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
09:18AM	5 Reasons Beam Therapeutics Remains a Risky Stock (Motley Fool)
Oct-27-23 07:15AM	The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical (Zacks)
Oct-25-23 06:30AM	Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT (GlobeNewswire)
05:50AM	Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble? (Motley Fool)
01:45AM	These Gene-Editing Stocks Are Survivors. Take Another Look. (Barrons.com)
Oct-21-23 08:45AM	Beam Therapeutics Stock: Bear vs. Bull (Motley Fool)
Oct-20-23 11:43AM	BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank (Zacks)
09:37AM	SolarEdge downgraded, Crocs upgraded: Wall Street's top analyst calls (The Fly)
Oct-19-23 09:03AM	UPDATE 2-Beam Therapeutics to cut 20% of workforce as part of restructuring plan (Reuters) -11.73%
08:54AM	Beam Therapeutics to cut 20% of workforce (Reuters)
08:45AM	Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline (GlobeNewswire)
Oct-18-23 09:30AM	1 Risky Biotech Stock to Consider Buying, and 1 to Avoid (Motley Fool) -6.60%
Oct-05-23 08:45AM	2 Cathie Wood Stocks I'm Bullish On (Motley Fool)
Oct-03-23 06:27AM	Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead? (Motley Fool)
Sep-29-23 10:30AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Sep-27-23 08:30AM	2 Magnificent Growth Stocks to Buy On the Dip (Motley Fool)

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Simon Amy	Chief Medical Officer	Jul 02 '24	Sale	22.95	748	17,167	68,805	Jul 03 04:05 PM
Simon Amy	Chief Medical Officer	Jul 01 '24	Sale	23.76	502	11,928	69,553	Jul 03 04:05 PM
Evans John M.	CEO	Jun 27 '24	Sale	24.50	60,000	1,470,156	998,343	Jun 28 04:15 PM
Simon Amy	Chief Medical Officer	Apr 02 '24	Sale	30.54	16,530	504,851	70,060	Apr 03 07:43 PM
Simon Amy	Chief Medical Officer	Apr 01 '24	Sale	32.13	7,157	229,954	86,590	Apr 03 07:43 PM
Bellon Christine	Chief Legal Officer	Apr 01 '24	Sale	32.12	3,401	109,240	104,594	Apr 03 07:40 PM
Burrell Terry-Ann	Chief Financial Officer	Apr 01 '24	Sale	32.12	5,446	174,926	70,137	Apr 03 07:39 PM
Evans John M.	CEO	Apr 01 '24	Sale	32.13	18,102	581,617	1,058,343	Apr 03 07:36 PM
Ciaramella Giuseppe	President	Apr 01 '24	Sale	32.12	4,534	145,632	169,616	Apr 03 07:33 PM
Evans John M.	CEO	Mar 28 '24	Sale	33.86	60,000	2,031,402	998,262	Apr 01 04:10 PM
FMR LLC	See Remark 1	Feb 14 '24	Sale	30.55	900,000	27,496,912	1,235,511	Feb 15 02:34 PM
FMR LLC	See Remark 1	Feb 13 '24	Sale	30.76	1,565	48,139	2,771,913	Feb 15 02:34 PM
Evans John M.	CEO	Jan 31 '24	Sale	25.33	60,000	1,519,800	1,058,262	Feb 02 04:05 PM
Bellon Christine	Chief Legal Officer	Jan 03 '24	Sale	26.42	1,907	50,383	80,495	Jan 05 04:30 PM
Bellon Christine	Chief Legal Officer	Nov 20 '23	Option Exercise	7.22	10,000	72,200	92,402	Nov 22 04:05 PM
Bellon Christine	Chief Legal Officer	Nov 20 '23	Sale	30.50	10,000	305,000	82,402	Nov 22 04:05 PM
Simon Amy	Chief Medical Officer	Oct 30 '23	Sale	18.70	3,448	64,478	65,469	Nov 01 04:30 PM
Ciaramella Giuseppe	President and CSO	Oct 20 '23	Option Exercise	0.67	90,900	60,903	139,150	Oct 24 04:05 PM
Bellon Christine	Chief Legal Officer	Oct 02 '23	Sale	22.85	388	8,866	82,402	Oct 04 04:30 PM

Open in Screener

RXRX

Recursion Pharmaceuticals Inc

Sep 20 • 03:01PM ET

6.82

Dollar change -0.12
Percentage change -1.80	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

RXRX Recursion Pharmaceuticals Inc daily Stock Chart

Held by: ARKK ARKG VTI VB IWM XBI VXF VBK IWO IBB

Index	RUT	P/E	-	EPS (ttm)	-1.62	Insider Own	22.61%	Shs Outstand	226.26M	Perf Week	3.73%
Market Cap	1.92B	Forward P/E	-	EPS next Y	-1.72	Insider Trans	-1.49%	Shs Float	218.42M	Perf Month	-10.56%
Income	-374.93M	PEG	-	EPS next Q	-0.33	Inst Own	77.16%	Short Float	25.65%	Perf Quarter	-22.99%
Sales	49.63M	P/S	38.76	EPS this Y	1.11%	Inst Trans	3.80%	Short Ratio	9.81	Perf Half Y	-36.01%
Book/sh	2.08	P/B	3.28	EPS next Y	-10.01%	ROA	-51.98%	Short Interest	56.03M	Perf Year	-16.17%
Cash/sh	1.69	P/C	4.04	EPS next 5Y	12.00%	ROE	-71.18%	52W Range	4.97 - 15.74	Perf YTD	-30.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-43.41%	ROI	-57.01%	52W High	-56.70%	Beta	0.81
Dividend TTM	-	Quick Ratio	6.07	Sales past 5Y	132.77%	Gross Margin	-31.81%	52W Low	37.12%	ATR (14)	0.43
Dividend Ex-Date	-	Current Ratio	6.07	EPS Y/Y TTM	-17.59%	Oper. Margin	-817.09%	RSI (14)	49.71	Volatility	5.46% 6.13%
Employees	-	Debt/Eq	0.15	Sales Y/Y TTM	-0.70%	Profit Margin	-755.37%	Recom	2.50	Target Price	10.14
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	-5.72%	Payout	-	Rel Volume	0.84	Prev Close	6.94
Sales Surprise	20.46%	EPS Surprise	-4.09%	Sales Q/Q	30.86%	Earnings	Aug 08 BMO	Avg Volume	5.71M	Price	6.82
SMA20	0.07%	SMA50	-5.21%	SMA200	-24.71%	Trades		Volume	4,092,377	Change	-1.80%

Date	Action	Analyst	Rating Change	Price Target Change
May-22-23	Initiated	Morgan Stanley	Equal-Weight	$8
Mar-16-23	Initiated	Needham	Buy	$17
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$20
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral	$10
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10
Sep-21-21	Initiated	Berenberg	Buy	$37
May-11-21	Initiated	SVB Leerink	Outperform	$33
May-11-21	Initiated	KeyBanc Capital Markets	Overweight	$36
May-11-21	Initiated	JP Morgan	Neutral	$32
May-11-21	Initiated	Goldman	Neutral	$34
May-11-21	Initiated	BofA Securities	Buy	$31

Show Previous Ratings

Today 08:30AM	Is Recursion Pharmaceuticals Stock a Buy? (Motley Fool)
Sep-12-24 10:53AM	Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock (Insider Monkey)
Sep-08-24 04:51PM	Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers (Insider Monkey)
11:49AM	10 Worst ARK Stocks To Buy According To Short Sellers (Insider Monkey)
Sep-03-24 08:00AM	Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability (GlobeNewswire) -16.62%
07:11AM	Loading…
07:11AM	AI specialist Recursion says lead drug is safe, but efficacy less clear (BioPharma Dive)
Aug-30-24 04:10AM	Is Recursion Pharmaceuticals a Warren Buffett Stock? (Motley Fool)
Aug-28-24 07:04PM	Recursion Pharmaceuticals Inc. (RXRX): Among The Best Medical AI Companies (Insider Monkey)
Aug-18-24 12:34PM	The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why. (Motley Fool)
Aug-17-24 09:53AM	Is Recursion Pharmaceuticals Stock a Buy? (Motley Fool)
Aug-16-24 06:36PM	These Stocks in Nvidia's Portfolio Took a Hit in the Second Quarter (Investopedia) +6.08%
Aug-14-24 09:45AM	How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates (GlobeNewswire)
Aug-13-24 07:05AM	Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks (Motley Fool) +8.46%
Aug-12-24 09:15AM	Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move (Motley Fool)
Aug-11-24 04:59AM	Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia? (Motley Fool)
05:37PM	Loading…
Aug-08-24 05:37PM	AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals (Benzinga) -5.27%
02:41PM	CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
08:45AM	Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:45AM	Recursion Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:39AM	Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities (GlobeNewswire)
07:30AM	Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
07:07AM	Biotech firm Recursion to buy smaller peer Exscientia for $688 million (Reuters)
01:32AM	Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT (GlobeNewswire)
Aug-06-24 06:00AM	Is Recursion Pharmaceuticals a Millionaire-Maker? (Motley Fool)
Aug-05-24 04:01PM	Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th (GlobeNewswire)
Jul-31-24 05:06AM	99.9% of Nvidia's $380 Million Investment Portfolio Has Been Put to Work in These 4 Artificial Intelligence (AI)-Inspired Stocks (Motley Fool)
Jul-29-24 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why (Zacks)
Jul-27-24 05:41AM	Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip? (Motley Fool)
Jul-26-24 09:55AM	Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know (Zacks)
Jul-18-24 06:10AM	3 Millionaire-Maker Artificial Intelligence (AI) Stocks (Motley Fool) -5.75%
06:25AM	Loading…
Jul-14-24 06:25AM	Is Recursion Pharmaceuticals Stock a Buy? (Motley Fool)
Jul-13-24 09:29AM	1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell (Motley Fool)
06:26AM	3 Healthcare Stocks Injecting AI for Big Gains (InvestorPlace)
Jul-12-24 05:50AM	These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street (Motley Fool) +8.85%
Jul-08-24 07:09PM	3 Longevity Stocks to Buy for Anti-Aging Breakthroughs (InvestorPlace)
Jul-03-24 09:12AM	3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030 (InvestorPlace)
Jun-28-24 10:28AM	Treasure Hunt: 3 Biotech Stocks Wall Street Hasn't Discovered Yet (InvestorPlace)
03:48AM	Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) (GuruFocus.com)
Jun-27-24 08:15AM	3 AI Stocks on the Edge of a Massive Surge (InvestorPlace) -13.53%
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Jun-26-24 10:07PM	Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock (GlobeNewswire) -6.61%
04:06PM	Recursion Announces Proposed Offering of Class A Common Stock (GlobeNewswire)
Jun-25-24 05:50PM	Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Jun-24-24 09:00AM	Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data (Business Wire) +5.54%
08:00AM	Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day (GlobeNewswire)
Jun-13-24 02:40PM	3 Stocks Under $10 Set to Quadruple by 2025: June Edition (InvestorPlace)
Jun-08-24 11:37AM	Nvidia Owns These 4 Stocks. Heres How Theyre Doing. (Barrons.com)
Jun-07-24 09:00AM	Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim (Motley Fool) -5.55%
Jun-05-24 06:26AM	Nvidia's Golden Handshake: 3 Stocks Reaping the Rewards of an NVDA Alliance (InvestorPlace) +8.09%
Jun-03-24 09:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
06:15AM	Cathie Wood Owns These 2 AI Stocks. Should You? (Motley Fool)
Jun-02-24 03:40AM	Is Recursion Pharmaceuticals Stock a Millionaire-Maker? (Motley Fool)
May-31-24 02:46AM	Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) (GuruFocus.com) -6.65%
May-30-24 04:46AM	Hedge Funds are Loading Up on This NVIDIA Corp (NVDA) Partner Stock (Insider Monkey)
04:32AM	7 Best Under-The-Radar AI Stocks Hedge Funds are Buying (Insider Monkey)
May-29-24 03:27PM	Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool (GlobeNewswire)
May-24-24 04:30PM	Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board (GlobeNewswire)
06:30AM	2 Stocks That Could 10x by 2035 (Motley Fool)
May-23-24 09:00AM	Here is What to Know Beyond Why Recursion Pharmaceuticals, Inc. (RXRX) is a Trending Stock (Zacks)
May-17-24 02:36AM	Director Blake Borgeson Sells 20,054 Shares of Recursion Pharmaceuticals Inc (RXRX) (GuruFocus.com)
May-15-24 08:45AM	What's the Difference Between Biotech Stocks and TechBio Stocks? (Motley Fool)
May-13-24 09:59AM	Recursion Pharmaceuticals Says BioHive-2 AI Supercomputer Completed (MT Newswires) +10.23%
05:00AM	Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry (GlobeNewswire)
May-12-24 08:15AM	Cathie Wood Is Buying This Under-the-Radar AI Stock (Motley Fool)
May-10-24 08:05PM	Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer (CNBC TV) +10.23%
01:26PM	Recursion Pharmaceuticals Inc (RXRX) Q1 2024 Earnings: Revenue Surpasses Estimates Amid ... (GuruFocus.com)
12:36PM	Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:59PM	RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:04PM	Recursion Pharmaceuticals Q1 Loss Widens, Revenue Rises (MT Newswires)
05:25PM	Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:32PM	Recursion Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-06-24 11:41AM	Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? (Zacks)
May-03-24 05:50PM	Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
May-02-24 09:00AM	Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know (Zacks) +5.40%
08:00AM	Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9 (GlobeNewswire)
May-01-24 08:01AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.65%
Apr-30-24 08:00AM	Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program (GlobeNewswire)
07:29AM	Jim Cramer is Recommending These 10 Stocks Heading Into May 2024 (Insider Monkey)
Apr-27-24 08:58AM	Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood Loves (Motley Fool)
07:00AM	The Top 3 Biotech Stocks to Buy in April 2024 (InvestorPlace)
Apr-25-24 05:50PM	Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors (Zacks)
10:30AM	3 Millionaire-Maker Biotech Stocks (Motley Fool)
08:01AM	AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029 (PR Newswire)
Apr-17-24 05:50PM	Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know (Zacks)
07:00AM	Where Will Recursion Pharmaceuticals Be in 5 Years? (Motley Fool)
Apr-16-24 08:00AM	Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer (GlobeNewswire)
Apr-15-24 12:54PM	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential (InvestorPlace) -7.37%
08:00AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024 (InvestorPlace)
Apr-10-24 05:50AM	Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take. (Motley Fool) -5.61%
Apr-08-24 09:00AM	The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation (Motley Fool)
Apr-04-24 08:45AM	Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy? (Motley Fool)
01:31AM	Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 11,447 Shares (GuruFocus.com)
Apr-03-24 09:35AM	Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a Turnaround (Zacks)
Apr-02-24 08:00AM	Recursion to Participate in Upcoming Investor Conference (GlobeNewswire) -6.40%
Apr-01-24 12:00PM	All You Need to Know About Recursion Pharmaceuticals (RXRX) Rating Upgrade to Buy (Zacks) -6.02%
Mar-26-24 08:00AM	Recursion Publishes Annual Environmental, Social and Governance Report (GlobeNewswire)
Mar-22-24 01:29AM	Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 20,054 Shares (GuruFocus.com)
Mar-18-24 01:00PM	New COVID-Like Outbreak 'Matter Of When, Not If,' WHO Director Warns As Scientists Race To Prepare Using Artificial Intelligence (Benzinga)
Mar-15-24 04:54PM	Since Nvidia Disclosed Stakes in These Stocks, They've Soared (Investopedia)

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Borgeson Blake	Director	Sep 17 '24	Sale	6.84	11,447	78,333	7,109,875	Sep 19 05:48 PM
Borgeson Blake	Director	Sep 17 '24	Proposed Sale	6.84	11,447	78,333		Sep 17 04:13 PM
Secora Michael	Chief Financial Officer	Sep 10 '24	Option Exercise	2.22	39,375	87,413	1,392,756	Sep 12 06:28 PM
Secora Michael	Chief Financial Officer	Sep 11 '24	Option Exercise	2.22	39,375	87,413	1,417,131	Sep 12 06:28 PM
Secora Michael	Chief Financial Officer	Sep 11 '24	Sale	6.32	15,000	94,730	1,402,131	Sep 12 06:28 PM
Secora Michael	Chief Financial Officer	Sep 10 '24	Sale	6.17	15,000	92,499	1,377,756	Sep 12 06:28 PM
Secora Michael	Officer	Sep 11 '24	Proposed Sale	6.32	15,000	94,730		Sep 11 05:15 PM
Secora Michael	Officer	Sep 10 '24	Proposed Sale	6.17	15,000	92,499		Sep 10 05:00 PM
Gibson Christopher	Chief Executive Officer	Sep 05 '24	Sale	6.14	20,000	122,800	762,656	Sep 06 04:57 PM
Gibson Christopher	Chief Executive Officer	Sep 04 '24	Sale	6.04	20,000	120,800	762,656	Sep 06 04:57 PM
Borgeson Blake	Director	Sep 03 '24	Sale	6.27	11,447	71,718	7,121,322	Sep 05 05:25 PM
Gibson Christopher	Officer	Sep 05 '24	Proposed Sale	6.14	20,000	122,800		Sep 05 11:43 AM
Gibson Christopher	Officer	Sep 04 '24	Proposed Sale	6.04	20,000	120,800		Sep 04 01:16 PM
Marriott Tina	President and COO	Aug 29 '24	Option Exercise	1.06	6,000	6,360	527,138	Sep 03 04:48 PM
Marriott Tina	President and COO	Aug 29 '24	Sale	7.56	6,000	45,376	521,138	Sep 03 04:48 PM
Borgeson Blake	Director	Sep 03 '24	Proposed Sale	6.27	11,447	71,717		Sep 03 04:27 PM
Gibson Christopher	Chief Executive Officer	Aug 30 '24	Option Exercise	2.48	5,000	12,400	762,656	Aug 30 04:26 PM
Marriott Tina	Officer	Aug 29 '24	Proposed Sale	7.56	6,000	45,376		Aug 29 04:53 PM
Gibson Christopher	Chief Executive Officer	Aug 29 '24	Option Exercise	2.48	5,000	12,400	757,656	Aug 29 04:22 PM
Gibson Christopher	Chief Executive Officer	Aug 28 '24	Option Exercise	2.48	5,000	12,400	752,656	Aug 28 04:12 PM
Gibson Christopher	Chief Executive Officer	Aug 27 '24	Option Exercise	2.48	5,000	12,400	747,656	Aug 27 04:10 PM
Gibson Christopher	Chief Executive Officer	Aug 26 '24	Option Exercise	2.48	5,000	12,400	742,656	Aug 26 04:42 PM
Gibson Christopher	Chief Executive Officer	Aug 23 '24	Option Exercise	2.48	5,000	12,400	737,656	Aug 23 05:25 PM
Borgeson Blake	Director	Aug 20 '24	Sale	7.12	11,447	81,532	7,132,769	Aug 22 06:48 PM
Borgeson Blake	Director	Aug 20 '24	Proposed Sale	7.12	11,447	81,533		Aug 20 04:25 PM
Secora Michael	Chief Financial Officer	Aug 13 '24	Option Exercise	2.22	39,375	87,413	1,355,968	Aug 15 05:24 PM
Secora Michael	Chief Financial Officer	Aug 14 '24	Option Exercise	2.22	39,375	87,413	1,380,343	Aug 15 05:24 PM
Secora Michael	Chief Financial Officer	Aug 14 '24	Sale	6.35	15,000	95,252	1,365,343	Aug 15 05:24 PM
Secora Michael	Chief Financial Officer	Aug 13 '24	Sale	6.35	15,000	95,182	1,340,968	Aug 15 05:24 PM
Secora Michael	Officer	Aug 14 '24	Proposed Sale	6.35	15,000	95,251		Aug 14 04:35 PM
Secora Michael	Officer	Aug 13 '24	Proposed Sale	6.35	15,000	95,183		Aug 13 04:22 PM
Gibson Christopher	Chief Executive Officer	Aug 07 '24	Sale	7.10	30,000	213,000	758,738	Aug 09 04:56 PM
Gibson Christopher	Chief Executive Officer	Aug 08 '24	Sale	6.50	20,000	130,000	758,738	Aug 09 04:56 PM
Borgeson Blake	Director	Aug 06 '24	Sale	6.82	11,447	78,083	7,144,216	Aug 08 05:23 PM
Gibson Christopher	Officer	Aug 08 '24	Proposed Sale	6.50	20,000	130,000		Aug 08 12:56 PM
Gibson Christopher	Officer	Aug 07 '24	Proposed Sale	7.10	30,000	213,000		Aug 07 01:34 PM
Borgeson Blake	Director	Aug 06 '24	Proposed Sale	6.82	11,447	78,083		Aug 06 04:50 PM
Marriott Tina	President and COO	Jul 25 '24	Option Exercise	1.06	6,000	6,360	541,457	Jul 29 06:16 PM
Marriott Tina	President and COO	Jul 25 '24	Sale	8.13	6,000	48,809	535,457	Jul 29 06:16 PM
Borgeson Blake	Director	Jul 23 '24	Sale	8.48	11,447	97,041	7,155,663	Jul 25 06:15 PM
Gibson Christopher	Chief Executive Officer	Jul 10 '24	Sale	7.48	50,000	374,000	758,738	Jul 12 06:54 PM
Gibson Christopher	Chief Executive Officer	Jul 11 '24	Sale	7.47	50,000	373,500	758,738	Jul 12 06:54 PM
Secora Michael	Chief Financial Officer	Jul 09 '24	Option Exercise	2.22	39,375	87,413	1,307,218	Jul 11 04:51 PM
Secora Michael	Chief Financial Officer	Jul 10 '24	Option Exercise	2.22	39,375	87,413	1,331,593	Jul 11 04:51 PM
Secora Michael	Chief Financial Officer	Jul 09 '24	Sale	7.32	15,000	109,778	1,292,218	Jul 11 04:51 PM
Secora Michael	Chief Financial Officer	Jul 10 '24	Sale	7.24	15,000	108,576	1,316,593	Jul 11 04:51 PM
Borgeson Blake	Director	Jul 09 '24	Sale	7.32	11,447	83,735	7,167,110	Jul 11 04:51 PM
Marriott Tina	President and COO	Jun 27 '24	Option Exercise	1.06	6,000	6,360	541,457	Jun 28 05:14 PM
Marriott Tina	President and COO	Jun 27 '24	Sale	7.21	6,000	43,290	535,457	Jun 28 05:14 PM
Borgeson Blake	Director	Jun 25 '24	Sale	9.51	11,447	108,806	7,177,116	Jun 27 07:13 PM
Secora Michael	Chief Financial Officer	Jun 13 '24	Option Exercise	2.22	39,375	87,413	1,258,468	Jun 17 05:46 PM
Secora Michael	Chief Financial Officer	Jun 14 '24	Option Exercise	2.22	39,375	87,413	1,282,843	Jun 17 05:46 PM
Secora Michael	Chief Financial Officer	Jun 13 '24	Sale	9.32	15,000	139,798	1,243,468	Jun 17 05:46 PM
Secora Michael	Chief Financial Officer	Jun 14 '24	Sale	9.27	15,000	139,082	1,267,843	Jun 17 05:46 PM
Borgeson Blake	Director	Jun 11 '24	Sale	8.45	11,447	96,763	7,188,563	Jun 13 05:36 PM
Gibson Christopher	Chief Executive Officer	Jun 06 '24	Sale	9.00	50,000	450,000	708,738	Jun 07 04:01 PM
Gibson Christopher	Chief Executive Officer	Jun 05 '24	Sale	8.42	50,000	421,000	758,738	Jun 07 04:01 PM
Marriott Tina	President and COO	May 30 '24	Option Exercise	1.06	3,000	3,180	538,457	Jun 03 06:31 PM
Marriott Tina	President and COO	May 30 '24	Sale	8.78	3,000	26,325	535,457	Jun 03 06:31 PM
Borgeson Blake	Director	May 28 '24	Sale	9.17	11,447	104,943	7,186,913	May 30 06:41 PM
Borgeson Blake	Director	May 14 '24	Sale	10.12	20,054	202,934	7,198,360	May 16 04:35 PM
Gibson Christopher	Chief Executive Officer	May 02 '24	Sale	8.47	50,000	423,500	834,820	May 03 06:24 PM
Gibson Christopher	Chief Executive Officer	May 01 '24	Sale	7.73	50,000	386,500	863,524	May 03 06:24 PM
Borgeson Blake	Director	Apr 30 '24	Sale	7.95	11,447	90,964	7,218,414	May 02 05:41 PM
Marriott Tina	President and COO	Apr 25 '24	Option Exercise	1.06	3,000	3,180	546,231	Apr 29 06:41 PM
Marriott Tina	President and COO	Apr 25 '24	Sale	7.67	3,000	23,020	543,231	Apr 29 06:41 PM
Borgeson Blake	Director	Apr 16 '24	Sale	7.66	11,447	87,725	7,229,861	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 16 '24	Option Exercise	2.22	37,500	83,250	1,241,679	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 17 '24	Option Exercise	2.22	37,500	83,250	1,254,179	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 16 '24	Sale	7.67	25,000	191,658	1,216,679	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 17 '24	Sale	7.58	23,124	175,349	1,231,055	Apr 18 05:12 PM
Gibson Christopher	Chief Executive Officer	Apr 04 '24	Sale	9.02	40,000	360,800	938,524	Apr 05 05:44 PM
Gibson Christopher	Chief Executive Officer	Apr 03 '24	Sale	8.84	40,000	353,600	978,524	Apr 05 05:44 PM
Gibson Christopher	Chief Executive Officer	Apr 04 '24	Sale	9.02	25,000	225,500	0	Apr 05 05:44 PM
Gibson Christopher	Chief Executive Officer	Apr 03 '24	Sale	8.84	25,000	221,000	0	Apr 05 05:44 PM
Borgeson Blake	Director	Apr 02 '24	Sale	8.82	11,447	100,942	7,241,308	Apr 03 05:42 PM
Gibson Christopher	Chief Executive Officer	Mar 28 '24	Sale	10.10	40,000	404,000	1,043,524	Apr 01 06:40 PM
Gibson Christopher	Chief Executive Officer	Mar 28 '24	Sale	10.10	25,000	252,500	0	Apr 01 06:40 PM
Marriott Tina	President and COO	Mar 21 '24	Option Exercise	1.06	8,000	8,480	647,982	Mar 25 06:39 PM
Marriott Tina	President and COO	Mar 21 '24	Sale	10.75	8,000	85,980	639,982	Mar 25 06:39 PM
Borgeson Blake	Director	Mar 19 '24	Sale	10.79	20,054	216,423	7,252,755	Mar 21 05:38 PM
Secora Michael	Chief Financial Officer	Mar 12 '24	Option Exercise	2.22	37,500	83,250	1,216,679	Mar 14 07:28 PM
Secora Michael	Chief Financial Officer	Mar 13 '24	Option Exercise	2.22	37,500	83,250	1,229,179	Mar 14 07:28 PM
Secora Michael	Chief Financial Officer	Mar 13 '24	Sale	11.03	25,000	275,815	1,204,179	Mar 14 07:28 PM
Secora Michael	Chief Financial Officer	Mar 12 '24	Sale	10.46	25,000	261,375	1,191,679	Mar 14 07:28 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '24	Option Exercise	4.42	39,924	176,384	1,144,843	Mar 08 07:08 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '24	Sale	11.86	36,319	430,682	1,108,524	Mar 08 07:08 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '24	Sale	11.55	25,000	288,823	0	Mar 08 07:08 PM
Borgeson Blake	Director	Mar 05 '24	Sale	12.06	20,054	241,805	7,272,809	Mar 07 06:53 PM
Marriott Tina	President and COO	Feb 22 '24	Option Exercise	1.06	8,000	8,480	647,982	Feb 23 07:22 PM
Marriott Tina	President and COO	Feb 22 '24	Sale	14.89	8,000	119,160	639,982	Feb 23 07:22 PM
Borgeson Blake	Director	Feb 20 '24	Sale	12.32	20,054	247,125	7,292,863	Feb 21 05:37 PM
Secora Michael	Chief Financial Officer	Feb 13 '24	Option Exercise	2.22	37,500	83,250	1,198,851	Feb 15 06:00 PM
Secora Michael	Chief Financial Officer	Feb 14 '24	Option Exercise	2.22	37,500	83,250	1,211,351	Feb 15 06:00 PM
Secora Michael	Chief Financial Officer	Feb 14 '24	Sale	10.46	25,000	261,425	1,186,351	Feb 15 06:00 PM
Secora Michael	Chief Financial Officer	Feb 13 '24	Sale	9.86	25,000	246,560	1,173,851	Feb 15 06:00 PM
Gibson Christopher	Chief Executive Officer	Feb 07 '24	Option Exercise	2.48	31,250	77,500	822,975	Feb 09 05:34 PM
Gibson Christopher	Chief Executive Officer	Feb 07 '24	Sale	9.22	48,272	444,981	774,703	Feb 09 05:34 PM
Borgeson Blake	Director	Feb 06 '24	Sale	9.30	11,447	106,489	7,312,917	Feb 08 06:54 PM
Larson Tina Marriott	President and COO	Jan 25 '24	Option Exercise	1.06	8,000	8,480	422,584	Jan 29 06:52 PM

BEAM

Beam Therapeutics Inc

RXRX

Recursion Pharmaceuticals Inc

Upgrade your FINVIZ experience